The application experience of Simponi (Golimumab) in the second line of biological therapy after Infliximab) in the patient with ulcerative colitis
Abstract
The article presents the clinical case analysis of the patient with diagnosis ulcerative colitis of overall affection with clinical-laboratory results. The patient received baseline therapy with transition to genetically engineered biological therapy with the medicine Infliximab. Due to the development of secondary resistance to the medicine infliximab Golimumab was prescribed. Golimumab was proved effective in the second line of biological therapy.
About the Authors
V. G. Ignatiev
North-Eastern federal university. Medical institute
Russian Federation
Russian Federation
Ignatiev Victor Georgievitch, PhD, professor, head of the general surgery department
V. M. Mikhailova
Republican hospital №2;
North-Eastern federal university. Medical institute
Russian Federation
Russian Federation
Mikhailova Valentina Mikhailovna, chief non-staff coloproctologist of Ministry of Health (Yakutia), head of coloproctology department;
Candidate of Medical Science, associate professor of the general surgery department
T. S. Dyagileva
North-Eastern federal university. Medical institute
Russian Federation
Russian Federation
Dyagileva Tatiana Semenovna, Candidate of Medical Science, associate professor of the general surgery department
I. A. Holtosunov
Republican hospital №2;
North-Eastern federal university. Medical institute
Russian Federation
Russian Federation
Holtosunov Ivan Afanasievitch, coloproctologist of the 2nd qualifi cation category of coloproctology department;
graduate student of the general surgery department
Mobile: 89247678767
L. A. Krivoshapkina
Republican hospital №2
Russian Federation
Russian Federation
Krivoshapkina Lena Aleksandrovna, coloproctologist of coloproctology department
References
1. Gastroenterology: national manual / under the editorship of V. T. Ivashkin, T. L. Lapina. – M.: GEOTAR-media, 2008. – 704 p.
2. Clinical recommendations about diagnostics and treatment of adult patients with ulcerative colitis V.T. / Ivashkin, Yu.A. Shelygin, D.I. Abdulganiyeva [et al.]. – M., 2015. - V.25. - №1. - 48-65 p.
3. Federal clinical recommendations about health care to children with ulcerative colitis / A.A. Baranov. – M., 2015.
4. Brown J. Aspects in the interdisciplinary decision-making for surgical intervention in ulcerative colitis and its complications / J. Brown, F. Meyer, J.M. Klapproth// Z Gastroenterol. 2012. - Vol. 50 (5). - Р. 468–474.
5. Lewis J. Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis/ Lewis J. // Inflamm Bowel Dis 2008;14:1660 – 1666.
6. Sandborn А. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis / А. Sandborn // Gastroenterology, 2014;146:85–95.24.
7. Second European convincingly sub-stantiated consensus on the diagnosis and management of ulcerative colitis / Axel Dignass // Journal of Crohn’s and Colitis (2012) 6, 965-990.
Review
For citations:
Ignatiev V.G., Mikhailova V.M., Dyagileva T.S., Holtosunov I.A., Krivoshapkina L.A. The application experience of Simponi (Golimumab) in the second line of biological therapy after Infliximab) in the patient with ulcerative colitis. Yakut Medical Journal. 2016;(4):75-77.
Views:
5
Email this article 